PMID- 30920851
OWN - NLM
STAT- MEDLINE
DCOM- 20190723
LR  - 20210504
IS  - 1744-7666 (Electronic)
IS  - 1465-6566 (Linking)
VI  - 20
IP  - 9
DP  - 2019 Jun
TI  - Dapagliflozin and cardiovascular outcomes: anything else to DECLARE?
PG  - 1087-1090
LID - 10.1080/14656566.2019.1598970 [doi]
AB  - Individuals with type 2 diabetes mellitus (T2DM) have increased cardiovascular 
      risk with regulatory agencies requiring cardiovascular outcome trials (CVOTs) for 
      the approval of new antidiabetic drugs. Areas covered: In this paper, the authors 
      critically discuss the background, trial design, results and implications of a 
      recent CVOT [NCT01730534; DECLARE-TIMI 58 study], which demonstrated that 
      dapagliflozin was non-inferior to placebo in terms of major adverse 
      cardiovascular events, and superior for the occurrence of hospitalization for 
      heart failure (HF) and composite renal endpoints, thus confirming the 
      cardiovascular benefit of sodium-glucose co-transporter-2 (SGLT2) inhibitors. No 
      statistically-significant effects were found for amputations, fractures, and 
      stroke (debated safety issues having emerged in previous CVOTs). Expert opinion: 
      DECLARE-TIMI 58 is the longest (4.2 years of follow up), largest (>17,000 
      participants) and most inclusive (only 41% of individuals with established 
      atherosclerotic cardiovascular disease) CVOT raising the debate towards SGLT2 
      inhibitor therapy in primary prevention and the potential use of these drugs also 
      in patients with HF without T2DM and other subpopulations.
FAU - Raschi, Emanuel
AU  - Raschi E
AD  - a Pharmacology Unit, Department of Medical and Surgical Sciences , University of 
      Bologna , Bologna , Italy.
FAU - Poluzzi, Elisabetta
AU  - Poluzzi E
AD  - a Pharmacology Unit, Department of Medical and Surgical Sciences , University of 
      Bologna , Bologna , Italy.
FAU - Marchesini, Giulio
AU  - Marchesini G
AD  - b Unit of Metabolic Diseases & Clinical Dietetics, Department of Medical and 
      Surgical Sciences , University of Bologna , Bologna , Italy.
FAU - De Ponti, Fabrizio
AU  - De Ponti F
AD  - a Pharmacology Unit, Department of Medical and Surgical Sciences , University of 
      Bologna , Bologna , Italy.
LA  - eng
PT  - Journal Article
DEP - 20190328
PL  - England
TA  - Expert Opin Pharmacother
JT  - Expert opinion on pharmacotherapy
JID - 100897346
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Glucosides)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - 1ULL0QJ8UC (dapagliflozin)
MH  - Benzhydryl Compounds/pharmacology/*therapeutic use
MH  - Cardiovascular Diseases/*drug therapy
MH  - Glucosides/pharmacology/*therapeutic use
MH  - Humans
MH  - Sodium-Glucose Transporter 2 Inhibitors/pharmacology/*therapeutic use
OTO - NOTNLM
OT  - Dapagliflozin
OT  - cardiovascular outcome trial
OT  - heart failure
OT  - major adverse cardiovascular events
OT  - sodium-glucose co-transporter-2 inhibitor
OT  - type 2 diabetes
EDAT- 2019/03/29 06:00
MHDA- 2019/07/25 06:00
CRDT- 2019/03/29 06:00
PHST- 2019/03/29 06:00 [pubmed]
PHST- 2019/07/25 06:00 [medline]
PHST- 2019/03/29 06:00 [entrez]
AID - 10.1080/14656566.2019.1598970 [doi]
PST - ppublish
SO  - Expert Opin Pharmacother. 2019 Jun;20(9):1087-1090. doi: 
      10.1080/14656566.2019.1598970. Epub 2019 Mar 28.